Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cellsDAMING SHAN; GOPAL, Ajay K; PRESS, Oliver W et al.Clinical cancer research. 2001, Vol 7, Num 8, pp 2490-2495, issn 1078-0432Article

Principles of radioimmunotherapy for hematologists and oncologistsPRESS, Oliver W; RASEY, Janet.Seminars in oncology. 2000, Vol 27, Num 6, pp 62-73, issn 0093-7754, SUP12Conference Paper

Physics for practitioners : The use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphomaPRESS, Oliver W.Seminars in hematology. 2000, Vol 37, Num 4, pp 2-8, issn 0037-1963, SUP7Article

Radioimmunotherapy for treatment of b-cell lymphomas and other hematologic malignanciesPARK, Steven I; PRESS, Oliver W.Current opinion in hematology. 2007, Vol 14, Num 6, pp 632-638, issn 1065-6251, 7 p.Article

Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspectivePRESS, Oliver W.Seminars in oncology. 2003, Vol 30, Num 2, pp 10-21, issn 0093-7754, 12 p., SUP4Article

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma : prospects for dual-targeted antibody/radioantibody therapySHARKEY, Robert M; PRESS, Oliver W; GOLDENBERG, David M et al.Blood. 2009, Vol 113, Num 17, pp 3891-3895, issn 0006-4971, 5 p.Article

A genetically engineered anti-CD45 single-chain antibody- streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignanciesYUKANG LIN; PAGEL, John M; AXWORTHY, Donald et al.Cancer research (Baltimore). 2006, Vol 66, Num 7, pp 3884-3892, issn 0008-5472, 9 p.Article

Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanismGOPAL, Ajay K; PAGEL, John M; HEDIN, Nathan et al.Blood. 2004, Vol 103, Num 9, pp 3516-3520, issn 0006-4971, 5 p.Article

Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin LymphomasPALANCA-WESSELS, M. Corinna A; PRESS, Oliver W.Cancer. 2010, Vol 116, Num 4, pp 1126-1133, issn 0008-543X, 8 p., SUPConference Paper

¹³¹I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaGOPAL, Ajay K; PAGEL, John M; FROMM, Jonathan R et al.Blood. 2009, Vol 113, Num 23, pp 5905-5910, issn 0006-4971, 6 p.Article

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaBUDDE, Lihua E; ZHANG, Michelle M; FRAYO, Shani L et al.British journal of haematology. 2013, Vol 161, Num 2, pp 183-191, issn 0007-1048, 9 p.Article

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + ¹³¹Iodine—TositumomabPRESS, Oliver W; UNGER, Joseph M; MALONEY, David G et al.Clinical cancer research (Print). 2013, Vol 19, Num 23, pp 6624-6632, issn 1078-0432, 9 p.Article

Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211NAKAMAE, Hirohisa; WILBUR, D. Scott; SANDMAIER, Brenda M et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 6, pp 2408-2415, issn 0008-5472, 8 p.Article

High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin Lymphoma : The Seattle ExperienceGOPAL, Ajay K; METCALFE, Tracee L; GOOLEY, Ted A et al.Cancer. 2008, Vol 113, Num 6, pp 1344-1350, issn 0008-543X, 7 p.Article

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domainsJINJUAN WANG; JENSEN, Michael; JAMES, Scott et al.Human gene therapy. 2007, Vol 18, Num 8, pp 712-725, issn 1043-0342, 14 p.Article

Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-β and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomasPAGEL, John M; LAUGEN, Christian; BONHAM, Lynn et al.Clinical cancer research. 2005, Vol 11, Num 13, pp 4857-4866, issn 1078-0432, 10 p.Article

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alonePERSKY, Daniel O; DORNAN, David; GOLDMAN, Bryan H et al.Haematologica (Roma). 2012, Vol 97, Num 6, pp 937-942, issn 0390-6078, 6 p.Article

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseasePARK, Steven I; SHENOI, Jaideep; YUKANG LIN et al.Blood. 2010, Vol 116, Num 20, pp 4231-4239, issn 0006-4971, 9 p.Article

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma : results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)THOMPSON, John A; FISHER, Richard I; LEBLANC, Michael et al.Blood. 2008, Vol 111, Num 8, pp 4048-4054, issn 0006-4971, 7 p.Article

^1I1I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionPAGEL, John M; APPELBAUM, Frederick R; CARRERAS, Jeanette et al.Blood. 2006, Vol 107, Num 5, pp 2184-2191, issn 0006-4971, 8 p.Article

New treatment options have changed the survival of patients with follicular lymphomaFISHER, Richard I; LEBLANC, Michael; PRESS, Oliver W et al.Journal of clinical oncology. 2005, Vol 23, Num 33, pp 8447-8452, issn 0732-183X, 6 p.Article

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's diseasePRESS, Oliver W; LEBLANC, Michael; LICHTER, Allen S et al.Journal of clinical oncology. 2001, Vol 19, Num 22, pp 4238-4244, issn 0732-183XArticle

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsTILL, Brian G; JENSEN, Michael C; RAUBITSCHEK, Andrew et al.Blood. 2012, Vol 119, Num 17, pp 3940-3950, issn 0006-4971, 11 p.Article

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelPAGEL, John M; KENOYER, Aimee L; OROZCO, Johnnie et al.Blood. 2011, Vol 118, Num 3, pp 703-711, issn 0006-4971, 9 p.Article

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. CommentaryCOOPER, Laurence J. N; TILL, Brian G; FORMAN, Stephen J et al.Blood. 2008, Vol 112, Num 6, issn 0006-4971, 2172-2173, 2261-2271 [13 p.]Article